TherapeuticsMD Q1 net loss $49M on flat revenue; completes $150M vitaCare sale

TherapeuticsMD, Inc.

2023-Q1 EPS reported -$5.70 vs consensus $0.06 ▼ miss (-9413.7%)

Total net product revenue $19.3M, down slightly from $19.6M Q1 2021.
Net loss $49.0M ($5.69 per share) vs $39.4M loss year ago; includes $8.4M debt extinguishment loss.
Cash $30.4M at March 31, down from $65.1M Dec 2021; used $120M vitaCare proceeds to reduce debt.
ANNOVERA prescriptions up 27% YoY to 8,014; new prescribers up 16% YoY.
Completed $150M divestiture of vitaCare in five weeks; $16M PIK fee waived.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.